Trevi Therapeutics Inc. (TRVI)
NASDAQ: TRVIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TRVI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.90B
- EPS (TTM)
- -$0.40
- Dividend yield
- None
- 52-week range
- 9.82 – 20.22
- Day range
- 13.23 – 13.90
- Volume / Avg
- 2.09M / 2.00M
- Beta
- —
- Shares outstanding
- 142.56M
52-week range
TRVI stock today
Trevi Therapeutics (TRVI) closed at $13.35 on Nov 20, down 2.70% (-$0.37), versus the S&P 500's 3.70% decline. Shares are 34.0% below their 52-week high of $20.22, set on Jul 17, 2026 and 35.9% above the 52-week low of $9.82, in the middle of the past year's range. TRVI is up 6.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 21.5%.
Trevi Therapeutics has posted a net loss over the last twelve months (EPS of -$0.40), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Trevi Therapeutics
Company profileTrevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Jennifer L. Good
- Headquarters
- New Haven, CT
- Employees
- 34
- IPO year
- 2019
- Website
- trevitherapeutics.com
Financial highlights
Full financialsTrevi Therapeutics reported a net loss of $42.8 million, compared with a loss of $47.9 million a year earlier. Diluted earnings per share came in at -$0.32.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-42.76M | $-47.91M | $-29.07M | $-29.15M | $-33.94M |
| EPS (diluted) | $-0.32 | $-0.47 | $-0.29 | $-0.45 | $-1.49 |
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$28.18+111.09%
- Strong buy 2
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.13 vs $-0.13
- Surprise
- 0.00%
TRVI news
All TRVI news- Trevi Therapeutics, Inc. Reports Third Quarter 2026 Financial ResultsNasdaq
- Trevi Therapeutics to Participate in Stifel's 2026 Healthcare ConferenceGlobeNewswire
- Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual MeetingGlobeNewswire
- After Hours Most Active for Oct 12, 2026 : NU, CMCSA, INDV, CTRI, NVDA, SNAP, TRVI, TJX, GOOGL, AMZN, CBZ, NOKNasdaqNU, CMCSA, INDV, CTRI
- After Hours Most Active for Oct 9, 2026 : FTXR, NVDA, BKD, GRAB, TRVI, URGN, INDV, LUV, WFC, ESI, OSG, BACNasdaqFTXR, NVDA, BKD, GRAB
Trevi Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| HRMYHarmony Biosciences Holdings Inc. | 32.59 | -1.18% | $1.91B | vs TRVI |
| BHVNBiohaven Ltd. | 12.39 | -9.23% | $1.87B | vs TRVI |
| IMNMImmunome Inc. | 15.69 | -5.54% | $1.85B | vs TRVI |
| VERAVera Therapeutics Inc. Class A | 25.45 | -4.86% | $1.84B | vs TRVI |
| AUPHAurinia Pharmaceuticals Inc | 14.70 | -1.28% | $1.97B | vs TRVI |
| SEPNSepterna Inc. | 38.61 | -1.51% | $1.84B | vs TRVI |
| MRVIMaravai LifeSciences Holdings Inc. Class A | 6.98 | -2.92% | $1.81B | vs TRVI |
| ZYMEZymeworks Inc. | 26.14 | -2.68% | $1.81B | vs TRVI |
Indexes, lists and sector
Trevi Therapeutics stock FAQ
What is Trevi Therapeutics's stock price today?
TRVI last traded at $13.35 as of Nov 20, 4:00 PM EST, down 2.70% on the day. Prices are delayed at least 15 minutes.
Who is Trevi Therapeutics's CEO?
Ms. Jennifer L. Good is the chief executive officer of Trevi Therapeutics Inc., which has about 34 employees.
What is the TRVI 52-week high?
The 52-week high for TRVI is $20.22 and the 52-week low is $9.82. The stock is currently 34.0% below its high.